Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01567891 · ClinicalTrials.gov registry record · Phase 1
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
A Phase 1 study, sponsored by Adaptimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01567891: Completed Phase 1 study, sponsored by Adaptimmune.
NCT01567891 is a Phase 1 study that has completed, run by Adaptimmune. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01567891, a Phase 1 study, has completed, sponsored by Adaptimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study, will take a subject's "T cells" and "teach" them to be able to recognize and attack the ovarian cancer cells. This is done by putting in a gene or genetic material that will change how a subject's T cells work and hopefully get them to attack and kill ovarian cancer cells. These new T cells are called "engineered T cells" because the new gene is causing them to become directed toward the ovarian cancer cells rather than their usual targets. These are also called "gene-modified T cells". For subjects who have the HLA A2 tissue-type marker, the T cells would be engineered to recognize a substance called "NY-ESO-1". After putting this new gene in T cells (a procedure called "gene therapy") the investigators will grow the cells in the laboratory and give these cells back to subjects.
Primary Outcome
Number of Participants with Adverse Events related to study treatment
Interventions
- BIOLOGICAL NYESO-1c259 T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-07-09 |
| Est. Completion | 2017-06-06 |
| Phase | Phase 1 |
What the finished NCT01567891 record still lists
NCT01567891 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which NYESO-1c259 T cells is the first listed.
NCT01567891 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01567891 about?
NCT01567891 is a clinical study titled "CT Antigen TCR-redirected T Cells for Ovarian Cancer.". This study, will take a subject's "T cells" and "teach" them to be able to recognize and attack the ovarian cancer cells. This is done by putting in a gene or genetic material that will change how a subject's T cells work and hopefully get them to attack and kill ovarian cancer cells. These new T ce...
What is the current status of trial NCT01567891?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-07-09. Estimated completion is 2017-06-06.
What interventions are being tested in trial NCT01567891?
The interventions under investigation include: NYESO-1c259 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01567891?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01567891's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI